The concentrated buying by the 10% owner signals strong internal conviction. Traders should watch for upcoming clinical catalysts (e.g., trial readouts or regulatory updates) that may have motivated the purchases. Consider building a position on further dips but monitor for any negative news.
PRTA drugs
PRTA drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 15 $8.15entry
- T+1 · 5mo ago +1.72%α +2.31% · $8.29
- T+5 · 5mo ago +12.27%α +13.65% · $9.15
- T+20 · 4mo ago +8.34%α +9.09% · $8.83
- T+60 · 2mo ago +14.11%α +13.11% · $9.30
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
10% owner William P. Scully purchased $1.49M of Prothena stock in two open-market transactions from June 4-11, 2026, at prices between $8.17 and $9.31. This represents ~0.34% of the $432M market cap and is a notable insider conviction signal, especially as prior insider buys in the last 30 days totaled $2.9M. The purchase comes amid a 67% analyst bullish consensus and adds to a pattern of insider buying.
Key Financial Metrics
Key Facts
- William P. Scully (10% owner) bought 175,000 shares total for $1.49M
- First trade: 50,000 shares at $9.31 on June 4; second: 125,000 shares at $8.17 on June 11
- Market cap of $432M makes this ~0.34% of company value
- Recent insider activity: 4 buys totaling $2.9M in the last 30 days
- Analyst consensus: 67% bullish (8 Buy, 3 Hold, 1 Sell)
Financial Impact
$1.49M insider purchase by 10% owner, ~0.34% of market cap
Risk Factors
- Clinical-stage biotech binary risk: trial failures could erase gains
- Single insider buy, even by a 10% owner, may not be replicated by other executives
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| INSIDER-BUY Data (Synthetic) | 0001045463-26-000007 |
Track record
20 reports on PRTA
7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +5.90% at T+5 after the Oct 29, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 13, 20263d ago 3 Neutral 1/10 Entry $8.16 to $7.97 Now $7.97 −2.33% ▼ −2.33% −0.42% vs SPY
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $8.16 to $7.97 Now $7.97 −2.33% ▼ −2.33% −0.42% vs SPY
- Nov 10, 20266d ago Insider Buy Bullish 5/10 Entry $8.56 to $8.73 Now $7.97 −6.89% ▲ +1.99% +0.67% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $7.97 to $8.78 Now $7.97 −0.00% ▲ +10.10% +7.73% vs SPY
- Oct 29, 202618d ago 8-K Bearish 6/10 Entry $8.47 to $8.29 Now $7.97 +5.90% ▲ +2.13% +1.65% vs SPY
- Oct 26, 202621d ago Insider Buy Bullish 5/10 Entry $8.81 to $9.10 Now $7.97 −9.53% ▲ +3.29% +2.95% vs SPY
- Oct 15, 20264w ago Insider Buy Bullish 5/10 Entry $8.35 to $8.48 Now $7.97 −4.55% ▲ +1.56% +1.13% vs SPY
- Sep 30, 20266w ago Insider Buy Bullish 5/10 Entry $8.54 to $8.36 Now $7.97 −6.67% ▼ −2.11% −2.85% vs SPY
- Sep 29, 20266w ago Insider Buy Bullish 5/10 Entry $8.38 to $8.54 Now $7.97 −4.89% ▲ +1.91% +1.73% vs SPY
- Sep 21, 20268w ago Insider Buy Bullish 6/10 Entry $8.99 to $8.68 Now $7.97 −11.35% ▼ −3.45% −2.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers